Chi Mei Medical Center
Tainan, Taiwan
15 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled279 locationsNCT07218380
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled565 locationsNCT07241390
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled353 locationsNCT06890598
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer
Regeneron Pharmaceuticals220 enrolled44 locationsNCT06787612
Recruiting
Phase 2Phase 3
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Metastatic Urothelial Cancer
BicycleTx Limited956 enrolled170 locationsNCT06225596
Recruiting
Phase 2
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Coherus Oncology, Inc.72 enrolled44 locationsNCT06679985
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled100 locationsNCT04752722
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled153 locationsNCT07062965
Recruiting
Phase 2
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Carcinoma, Non-Small Cell LungAdenocarcinoma of Lung
Lantern Pharma Inc.90 enrolled16 locationsNCT05456256
Recruiting
Phase 1Phase 2
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd.49 enrolled5 locationsNCT05326243
Recruiting
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd.49 enrolled5 locationsNCT05377307
Recruiting
Phase 2
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Gastric Cancer
Aston Sci. Inc.24 enrolled6 locationsNCT05771584